This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Cerevel Therapeutics Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Cerevel Therapeutics Holdings's earnings have been declining at an average annual rate of -30.8%, while the Biotechs industry saw earnings growing at 16.1% annually.
Anahtar bilgiler
-30.8%
Kazanç büyüme oranı
-3.6%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | n/a |
Özkaynak getirisi | -81.6% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Gelir ve Gider Dağılımı
Cerevel Therapeutics Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Mar 24 | 0 | -460 | 127 | 363 |
31 Dec 23 | 0 | -433 | 113 | 335 |
30 Sep 23 | 0 | -393 | 96 | 319 |
30 Jun 23 | 0 | -397 | 94 | 305 |
31 Mar 23 | 0 | -388 | 91 | 303 |
31 Dec 22 | 0 | -352 | 88 | 280 |
30 Sep 22 | 0 | -318 | 78 | 247 |
30 Jun 22 | 0 | -280 | 69 | 216 |
31 Mar 22 | 0 | -243 | 61 | 180 |
31 Dec 21 | 0 | -225 | 58 | 162 |
30 Sep 21 | 0 | -196 | 45 | 144 |
30 Jun 21 | 0 | -173 | 44 | 128 |
31 Mar 21 | 0 | -146 | 41 | 113 |
31 Dec 20 | 0 | -148 | 40 | 103 |
30 Sep 20 | 0 | -175 | 48 | 95 |
30 Jun 20 | 0 | -172 | 45 | 88 |
31 Mar 20 | 0 | -151 | 40 | 73 |
31 Dec 19 | 0 | -128 | 33 | 50 |
Kaliteli Kazançlar: CERE is currently unprofitable.
Büyüyen Kar Marjı: CERE is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CERE is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.
Büyüme Hızlandırma: Unable to compare CERE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CERE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-34.5%).
Özkaynak Getirisi
Yüksek ROE: CERE has a negative Return on Equity (-81.58%), as it is currently unprofitable.